InSitu Biologics

InSitu Biologics is a private, pre-revenue biotech firm developing a novel hydrogel-based drug delivery platform for localized, extended-release treatment of pain, cancer, and infection. Its lead program, INSB200™, targets peri-operative pain management and is approaching Phase 1 clinical trials, while INSB400™ is an early-stage oncology product. The company leverages a seasoned leadership team with strong academic and industry ties, including a recent license agreement with Mayo Clinic, to address multi-billion dollar market opportunities in non-opioid pain management and targeted oncology.

Proprietary multi-phase prolonged-release hydrogel drug delivery platform for localized treatment.

InSitu competes in the crowded non-opioid pain management space against other extended-release local anesthetics, nerve block technologies, and systemic non-opioid drugs. In targeted oncology, it faces competition from other drug-eluting implant technologies, nanoparticle delivery systems, and established locoregional therapies.